Skip to main content
Premium Trial:

Request an Annual Quote

Quest to Use Orchid s Technology in Diagnostic Tests

NEW YORK, Dec. 14 – Orchid BioSciences said Friday it had granted Quest Diagnostics a non-exclusive license to use its SNP-IT technology in its diagnostic tests.

This deal marks the first time Orchid’s technology has been licensed for use in diagnostics.

Under the terms of the deal, Orchid of Princeton, NJ, received an upfront payment of an undisclosed amount and will also be entitled to royalties for diagnostic services Quest provides using Orchid’s technology.

Quest of Teterboro, NJ, has gained access to the SNP-IT technology through a deal with Applied Biosystems for its SNAPshot reagent kits. Orchid’s SNP-IT technology is embedded in the reagent kits, which Applied Biosystems markets. 

However, SNAPshot users aiming to provide commercial genotyping services must obtain an additional license from Orchid. 

"We are leveraging our initial propagation partnership with Applied Biosystems, which provides Orchid with an ongoing royalty stream on sales of SNAPshot kits, to establish a beachhead for our market leading SNP-IT technology in the critical clinical diagnostics services arena,” Russell Granzow, vice president of corporate development and strategy at Orchid, said in a statement.

Granzow noted that he expected to pen similar deals in the future.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more